Rising like the phoenix?

@article{Plow2014RisingLT,
  title={Rising like the phoenix?},
  author={E. Plow and Mitali Das},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  year={2014},
  volume={34 10},
  pages={
          2182-3
        }
}
  • E. Plow, Mitali Das
  • Published 2014
  • Medicine
  • Arteriosclerosis, thrombosis, and vascular biology
Depending on one’s perspective, αIIbβ3 antagonists can be viewed as a great success story or as an exasperating disappointment.1 Certainly, millions of patients have been treated with the 3 Food and Drug Administration–approved αIIbβ3 antagonists, abciximab, eptifibatide, tirofiban; based on their reduction in mortality in clinical trials, one can calculate that many lives have been saved by these drugs2 and they continue to be administered to prevent thrombotic events, primarily in the setting… Expand
5 Citations
Platelets: Context-Dependent Vascular Protectors or Mediators of Disease.
  • 5
Novel Antiplatelet Therapies for Atherothrombotic Diseases
  • 13
Advancement in integrin facilitated drug delivery.
  • 82
A New Dawn in Nationalism Studies? Some Fresh Incentives to Overcome Historiographical Nationalism
  • E. Storm
  • Political Science, Medicine
  • European history quarterly
  • 2018
  • 4

References

SHOWING 1-10 OF 22 REFERENCES
Oral GPIIb/IIIa antagonists: what went wrong?
  • D. Cox
  • Medicine
  • Current pharmaceutical design
  • 2004
  • 67
RUC-4: A Novel &agr;IIb&bgr;3 Antagonist for Prehospital Therapy of Myocardial Infarction
  • 31
  • PDF
Translating from the rivers of Babylon to the coronary bloodstream.
  • B. Coller
  • Medicine
  • The Journal of clinical investigation
  • 2012
  • 15
  • PDF
...
1
2
3
...